Spec. MD. Ender Kalacı
Medical Specialist
Areas Of Interests
Gastrointestinal system tumors (Colorectal cancer
Stomach cancer
Esophageal cancer)
Gynecological Cancers (Ovarian cancer
Cervical cancer
Endometrial cancer)
Sarcomas (soft tissue and bone sarcomas)
Breast cancer
Lung cancer
Molecular oncology and personalized treatment approaches
Geriatric oncology
Palliative Care
Cancer screening and early detection programs
Cancer Prevention
Education:
- Ankara University Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology, Ankara, TURKEY, Medical Oncology Subspecialty Training, 2019-2023
- Ankara University Faculty of Medicine, Department of Internal Medicine, Ankara, TURKEY, Internal Medicine Specialty Training, 2014-2018
- Akdeniz University Faculty of Medicine, Antalya, TURKEY, Faculty of Medicine, 2006-2012
- Niğde Ömer Halisdemir Training and Research Hospital, Internal Medicine Specialist (Compulsory State Service), 2018-2019
- Bitlis Tatvan State Hospital, Medical Oncology Specialist (Compulsory State Service), August 2023 – June 2024
- Düzgün N, Kalacı E, Okatan IE, Heper Okçu A. Refractory to Rituximab-Based B-Cell Depletion Therapy on Chronic Skin Manifestations of Systemic Lupus Erythematosus : Case Report. Journal of Dermatology and Clinical Research 2017 May 31.
- Sahin Eroglu D, Dalva K, Kalaci E, Toprak SK, Civriz Bozdag S, Topcuoglu P, Demirer T, Gurman G, Yuksel MK. Prospective Follow-up of Panel Reactive Antibodies From Diagnosis Until Completion of Therapy Including Allogeneic Stem Cell Transplantation Among Patients With Acute Leukemia. Exp Clin Transplant. 2021 Apr 29. doi: 10.6002/ect.2020.0524. Epub ahead of print. PMID: 33928875.
- Gürbüz M, Doğan İ, Akkuş E, Özakıncı H, Kubilay Tolunay P, Kalacı E, Bağlan T, Köksoy EB, Ceyhan K, Dizbay Sak S, Aydıner A, Demirkazık A, Utkan G. The relationship between clinicopathological parameters and PD-L1 expression level in advanced stage non-small cell lung cancer. Tuberk Toraks. 2022 Jun;70(2):132-140. English. doi: 10.5578/tt.20229803. PMID: 35785877.
- Yekedüz E, Köksoy EB, Yazgan SS, Akbıyık I, Balli S, Kavak EE, Kalaci E, Dursun B, Kubilay Tolunay P, Gürbüz M, Akbulut H, Demirkazik A, Çay Şenler F, Utkan G, Ürün Y. Seasonal influenza and pneumococcal vaccination rates among patients with cancer in covid-19 pandemic: A cross-sectional study. Journal of Oncological Science, 7.2 (2021). DOI: 10.37047/jos.2021-83087
- Kalaci E, Ürün Y. Nivolumab-induced immune-related neutropenia in a renal cell carcinoma patient. J Oncol Pharm Pract. 2023;29(7):1797-1801. doi:10.1177/10781552231186748
- Hamdard, J., Bilici, A., Sakin, A., Kahraman, S., Yasin, A. I., Kalaci, E., Gokmen, I., Acikgoz, O., Kutlu, Y., Sendur, M. A. N., Olmez, O. F., & Seker, M. (2024). Characteristic features and prognostic factors in gastric cancer patients with bone metastases: multicenter experience. Journal of chemotherapy (Florence, Italy), 1–10. Advance online publication. https://doi.org/10.1080/1120009X.2024.2358458
- KALACI, E., EROĞLU, D. Ş., SEVAL, G. C., ÖZCAN, M., TOPÇUOĞLU, P., TOPRAK, S. K., ... BOZDAĞ, S. C.(2024). Effects of Cytomegalovirus Reactivation Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia: A Retrospective Analysis. Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , vol.8, no.2, 65-72.
- Dökmetaş, M., Muğlu, H., Özcan, E., Bayram Kuvvet, B., Helvacı, K., Kalacı E., Kahraman, S., Aykan, M. B., Çiçin, İ., Selçukbiricik, F., Ölmez, Ö. F., & Bilici, A. (2025). Endocrine Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis. Medicina (Kaunas, Lithuania), 61(1), 123. https://doi.org/10.3390/medicina61010123
- Kalaci E, Köksoy EB, Akbiyik I, Dursun B, Utkan G. Real-world treatment compliance and outcomes in adult patients with localized Ewing sarcoma: A single-institution retrospective study. Medicine (Baltimore). 2025 Jul 18;104(29):e43405. doi: 10.1097/MD.0000000000043405. PMID: 40696651; PMCID: PMC12282683.
